NSIS-B π Novonesis (Novozymes) - Overview
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060336014
NSIS-B: Enzymes, Microorganisms, Probiotics, Cleaning Products, Agriculture Solutions
Novonesis A/S, a Denmark-based company, specializes in the production and sale of industrial enzymes, microorganisms, and probiotics, catering to a diverse range of markets globally, including Denmark, Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and other international regions. The company's product portfolio includes protein solutions designed specifically for the food and beverage industry, addressing the needs of manufacturers in these sectors. Additionally, Novonesis A/S offers an array of services and solutions for industrial hygiene, including drain openers, hard surface cleaning, medical cleaning, septic tank maintenance, ware washing, and professional laundry services, underscoring its commitment to providing comprehensive support to various industries.
Further expanding its offerings, the company provides a wide range of agricultural solutions, including those for corn, cotton, forages, peanuts, pulses, soybeans, wheat, and small grains, as well as bioyield and biocontrol solutions. This demonstrates Novonesis A/S's significant involvement in the agricultural sector, aiming to enhance crop yields and disease resistance through its biological products. Moreover, the company addresses the needs of the aquaculture industry with solutions for warm water species and recirculating aquaculture systems, and it offers animal health and nutrition solutions, highlighting its diverse capabilities in supporting sustainable animal husbandry practices.
Novonesis A/S also delves into the realm of industrial processes with its fiber modification, bleach boosting, deposit control, and starch modification solutions, which are crucial for the efficient operation of various manufacturing processes. The company's commitment to sustainability is evident in its carbon capture, leather and textiles solutions, showcasing its efforts to reduce environmental impact across different industries. Its enzyme solutions, encompassing a broad spectrum of applications from corn and wheat separation to specialties, are pivotal in enhancing the efficiency and reducing the environmental footprint of industrial processes.
In the human health sector, Novonesis A/S provides solutions targeting brain, oral, protective and immune, and gastrointestinal health, leveraging the potential of probiotics and enzymes to support well-being. The company's engagement with the bioenergy sector is marked by its solutions for ethanol, biodiesel, and renewable diesel production, aiming to contribute to the transition towards more sustainable energy sources. Moreover, its involvement in agriculture and industry is complemented by biogas, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions, reflecting a comprehensive approach to supporting sustainable practices and reducing waste.
Novonesis A/S's product lineup includes a variety of enzymes such as lipases, proteases, oxidoreductases, and carbohydrases, which are fundamental in numerous industrial and biological processes. Founded in 1925 and headquartered in Bagsvaerd, Denmark, the company has established itself as a significant player in the specialty chemicals industry, with a web presence at https://www.novonesis.com and listed with the ISIN DK0060336014 as a common stock under the GICS Sub Industry: Specialty Chemicals.
Additional Sources for NSIS-B Stock
NSIS-B Stock Overview
Market Cap in USD | 27,203m |
Sector | Basic Materials |
Industry | Specialty Chemicals |
GiC Sub-Industry | Specialty Chemicals |
IPO / Inception |
NSIS-B Stock Ratings
Growth 5y | 29.3% |
Fundamental | 23.0% |
Dividend | 40.4% |
Rel. Strength Industry | 8031 |
Analysts | - |
Fair Price Momentum | 384.07 DKK |
Fair Price DCF | 287.30 DKK |
NSIS-B Dividends
Dividend Yield 12m | 0.99% |
Yield on Cost 5y | 1.33% |
Annual Growth 5y | 15.33% |
Payout Consistency | 99.8% |
NSIS-B Growth Ratios
Growth Correlation 3m | -84.9% |
Growth Correlation 12m | 71.1% |
Growth Correlation 5y | 19.6% |
CAGR 5y | 6.12% |
CAGR/Mean DD 5y | 0.36 |
Sharpe Ratio 12m | 0.37 |
Alpha | -3.74 |
Beta | 0.47 |
Volatility | 23.66% |
Current Volume | 1301.3k |
Average Volume 20d | 640.9k |
As of December 21, 2024, the stock is trading at DKK 404.80 with a total of 1,301,330 shares traded.
Over the past week, the price has changed by -3.93%, over one month by +1.28%, over three months by -10.80% and over the past year by +12.27%.
Neither. Based on ValueRay Fundamental Analyses, Novonesis (Novozymes) is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 22.96 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NSIS-B as of December 2024 is 384.07. This means that NSIS-B is currently overvalued and has a potential downside of -5.12%.
Novonesis (Novozymes) has no consensus analysts rating.
According to ValueRays Forecast Model, NSIS-B Novonesis (Novozymes) will be worth about 418.6 in December 2025. The stock is currently trading at 404.80. This means that the stock has a potential upside of +3.42%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 487.7 | 20.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 418.6 | 3.4% |